Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.

Obesity Clinical Trial

Official title:

A Prospective, Randomized, Open Label, Parallel, 16-week Study to Explore and Evaluate the Therapeutic Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese Patients With T2DM Inadequately Controlled With Metformin Monotherapy.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03961659
• Other study ID #: ZZ2019
• Status: Recruiting
• Phase: N/A
• Start date: May 2019
• Est. completion date: February 2021

Study information

• Verified date: May 2019
• Source: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• Contact: Da long Zhu, MD, PhD
• Phone: 86-25-83-105302
• Email: zhudldr[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized, open label, parallel, 16-week study to explore and evaluate the therapeutic effects of liraglutid, dapagliflozin and acarbose on the cognitive function, olfactory function, and odor-induced brain activation in overweight/obese patients with type 2 diabetes mellitus(T2DM) inadequately controlled with metformin monotherapy.

Description:

This is a prospective, randomized, open label, parallel, 16-week study to explore and evaluate the therapeutic effects of liraglutid, dapagliflozin and acarbose on the cognitive function, olfactory function, and odor-induced brain activation in overweight/obese patients with T2DM inadequately controlled with metformin monotherapy.We have 1 principle investigator, 6 sub-investigators and 1 nurse in research centre. The sub-investigators will screen in the outpatient and inpatient departments to enroll 87 patients (29 for each arm) totally with the inclusion and exclusion criteria in 12 months. The patients will be randomized at a 1:1:1 ratio into liraglutid, dapagliflozin and acarbose treatment group with a computer-generated random order. All patients will also continue on their existing dose and regimen of metformin throughout the study. At the baseline, clinical information collection, 100g-steamed bread meal test, biochemical measurement, body composition analysis, cognitive assessment, olfactory test and functional magnetic resonance imaging(fMRI) scan will be conducted for all patients. During the treatment period, visits at 4-week intervals will be performed to evaluate the safety of drugs and adjust the dose of metformin if hypoglycaemia occurs; meanwhile, fasting and 2-hour postprandial plasma glucose assayed by fingerstick, physical examination, and olfactory test will be conducted. At the end of the study, all of the assessments will be performed again for all recruited subjects, including early withdrawal patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 87
• Est. completion date: February 2021
• Est. primary completion date: August 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age ? 40 and ?75 years old

• T2DM patients controlled with metformin monotherapy with stable, maximum tolerated doses (?1500mg/d, ?12 weeks)

• HbA1c>7% and =9%

• Body mass index(BMI) =25kg/m2 and with stable weight during previous 3 months

• Right handedness

• Possessed over 6-year education

• Provision of informed consent prior to any study specific procedures

• Mini-Mental State Examination (MMSE) >24

Exclusion Criteria:

• Allergies to research drugs

• Treated with glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors, insulins, and glycosidase inhibitors in the previous 6 months

• Moderate to severe renal dysfunction defined as estimated glomerular filtration rate(eGFR)<60ml/min/1.73m2 ( eGFR was estimated by CKD-EPI creatinine equation using an online calculator).

• Hepatic insufficiency

• A history of neurological and psychiatric disorders, nasal pathologies, abnormal thyroid, pancreatitis, repeated urinary tract infection, chronic gastrointestinal dysfunction, any disease that may worsen by intestinal flatulence, alcohol or substance abuse, steroid treatment

• Any acute disease

• Inability to undergo tests or MRI scanning

• Pregnant or lactating women

• Participating in other clinical trials at the same time or within 6 months prior to the start of the trial

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Cognitive Impairment
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Obesity
• Overweight
• Type 2 Diabetes Mellitus

Intervention

Drug:
• Liraglutid
Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
• Dapagliflozin
Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
• Acarbose
Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.

Locations

Country	Name	City	State
China	at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of olfactory brain activation by fMRI	Compare the change of olfactory brain activation by fMRI from baseline to 16 weeks' follow-up	from baseline to 16 weeks' follow-up.
Secondary	Change of cognitive function	Compare the change of Montreal Cognitive Assessment (MoCA, beijing version) from baseline to 16 weeks' follow-up. MoCA score(ranging from 0 to 30)<26 is considered cognitive impairment and when the score is lower, the cognitive impairment is more serious. MoCA score =26 is considered normal cognition.	from baseline to 16 weeks' follow-up.
Secondary	Proportion of patients whose MoCA<26 scores	Compare the proportion of patients whose MoCA<26 scores at baseline and at 16 weeks' follow-up.	at baseline and at 16 weeks' follow-up.
Secondary	Change of blood glycaemic control	Compare the change of glycosylated hemoglobin(HbA1c) from baseline to 16 weeks' follow-up	from baseline to 16 weeks' follow-up
Secondary	Proportion of patients whose HbA1c<7%	Analyze the proportion of patients whose HbA1c<7% at 16 weeks' follow-up.	at 16 weeks' follow-up.
Secondary	Proportion of patients whose weight loss>3% and >5%	Analyze the proportion of patients whose weight loss>3% and >5%	from baseline to 16 weeks' follow-up.
Secondary	Olfactory threshold test	The olfactory threshold test (score range 1-13.5) is determined based on a series of binary dilutions of the N-butanol solution in light mineral oil. The higher the score is, the more sensitive the participant is in detecting an odor. Scores of 8-10 were considered normal olfactory sensitivity, whereas scores of 1-3 signified olfactory dysfunction or anosmia, and scores of =10 indicate better olfactory sensitivity.	from baseline to 16 weeks' follow-up.